PEPTIDES & VITAMINS
Sermorelin
A prescription peptide that prompts pituitary growth-hormone signaling in carefully evaluated adults.
What it is
Sermorelin is a synthetic analogue of growth hormone-releasing hormone. It is used under medical supervision to stimulate the pituitary gland rather than supplying growth hormone itself.
How it works
The peptide binds to receptors in the pituitary and encourages pulsatile growth hormone release. A clinician reviews medical history, symptoms, and relevant laboratory data before prescribing. Response and adverse effects are assessed during follow-up.
Who it is for
- Adults whose symptoms warrant a physician-directed hormonal evaluation
- Patients willing to use a scheduled subcutaneous injection
- Patients seeking care within a monitored peptide protocol
Mechanism in depth
Sermorelin is a synthetic analog of growth hormone releasing hormone. It binds pituitary receptors and prompts pulsatile release of the body's own growth hormone, which then signals the liver and other tissues to produce IGF-1. Because the pituitary retains negative feedback control, the risk of supraphysiologic peaks is lower than direct injection of recombinant growth hormone.
What outcomes to expect
Reported effects include improved sleep quality and recovery within the first several weeks. Body composition, skin, and energy changes are more gradual and depend heavily on diet, training, and sleep hygiene. Response varies with age and baseline pituitary function — younger patients with functional pituitary tissue tend to respond more predictably.
Individual response varies. GPLX does not guarantee results. Your physician sets expectations based on your health history and lab findings.
Common side effects
The most common local effect is injection site irritation. Systemic effects can include mild flushing, headache, and initial water retention. Rare concerns include altered glucose tolerance in susceptible patients. Sermorelin does not raise IGF-1 as high as recombinant HGH, which is part of its safety argument.
Monitoring schedule
GPLX typically reviews baseline labs including IGF-1, fasting glucose, and HbA1c. Follow-up labs occur at six to eight weeks and then every three to six months. Symptom tracking is part of every visit.
Not appropriate if
Not appropriate if you have an active malignancy, uncontrolled diabetes, a known pituitary disorder, severe respiratory disease, or if pregnancy is possible. Sermorelin is not used in growth-hormone-deficient children through GPLX.
Biomarkers reviewed with this treatment
Your physician reviews these markers before and during therapy. Click any marker for a plain-English explanation of what it measures and why it matters.
This treatment is only available after a physician consultation. Membership $39.99/month; consultation $30. Labs and medications billed separately.
Start Your Consultation